Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Neurofibromatosis Type 2 (NF2), which is a genetic disorder that causes tumors to grow on nerves, particularly affecting the nerves responsible for hearing. The study is specifically looking at a type of tumor called vestibular schwannomas, which can lead to hearing loss. The treatment being investigated is called 89Zr-Bevacizumab, which is a special form of a drug that is used to help visualize these tumors using a type of imaging called PET/CT scan. This imaging technique combines two methods: positron emission tomography (PET) and computed tomography (CT), to provide detailed pictures of the inside of the body.

The purpose of the study is to see if the 89Zr-Bevacizumab PET/CT scan can predict how well patients with NF2 will respond to treatment with Bevacizumab, a medication that is used to treat these tumors. During the study, participants will undergo the PET/CT scan before starting their treatment with Bevacizumab. The researchers will then monitor the participants to see if there is a correlation between the scan results and improvements in hearing or changes in the size of the tumors.

Throughout the study, the researchers will also look at other factors such as how the treatment affects the patients' overall well-being, balance, and function of other nerves. The study aims to provide valuable information that could help improve the management of NF2 and potentially enhance the quality of life for those affected by this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, diagnosis of NF2-related schwannomatosis, and measurable disease through MRI scans.

    Written informed consent is required before proceeding.

  2. Step 2

    Pre-treatment imaging

    A PET/CT scan using 89Zr-Bevacizumab is performed. This imaging helps predict the response to future treatment.

    The scan involves an intravenous injection of the tracer, which is a form of imaging that helps visualize the tumors.

  3. Step 3

    Treatment planning

    Based on the imaging results, a treatment plan with bevacizumab is prepared. This plan is tailored to the individual's condition and response predictions.

  4. Step 4

    Bevacizumab treatment

    The treatment involves regular administration of bevacizumab. The dosage and frequency are determined by the healthcare provider based on the treatment plan.

    The goal is to assess the hearing response and other outcomes as predicted by the initial imaging.

  5. Step 5

    Ongoing assessments

    Throughout the treatment, regular assessments are conducted to monitor hearing, vestibular function, and other health parameters.

    These assessments help evaluate the effectiveness of the treatment and adjust the plan if necessary.

  6. Step 6

    Final evaluation

    At the end of the treatment period, a final evaluation is conducted to assess the overall response to the treatment.

    This includes a review of hearing response, radiographic response, and any changes in other health parameters.

Who can join the trial?

5 criteria

  • Patients must be 18 years or older.
  • Must have a confirmed diagnosis of NF2, which is a specific medical condition, using certain criteria.
  • Must have provided written informed consent, meaning they agree to participate after understanding the study details.
  • Must have a measurable disease, which means having at least one vestibular schwannoma (a type of tumor) larger than 0.4 ml that can be measured using a special MRI scan.
  • Must be eligible and planned for bevacizumab treatment, which is a specific type of medication used in the study.

Who cannot join the trial?

3 criteria

  • Patients who do not have NF2-related schwannomatosis cannot participate. This is a specific condition involving nerve tumors.
  • Patients who are not within the specified age range cannot participate. The study includes both children and adults.
  • Patients who are part of a vulnerable population cannot participate. This means people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Bevacizumab is a medication used in this trial to treat patients with vestibular schwannomas, which are tumors associated with neurofibromatosis type 2. The trial aims to see if a special imaging technique can predict how well patients will respond to this treatment. Bevacizumab works by blocking a protein that helps tumors grow new blood vessels, which can slow down or stop the growth of the tumor.

What is already known about the treatment

Bevacizumab – Bevacizumab is administered intravenously and is used in the treatment of various types of cancer. It is currently being studied for its effectiveness in treating NF2-related schwannomatosis, particularly vestibular schwannomas. The medication works by inhibiting vascular endothelial growth factor (VEGF), which reduces the growth of blood vessels that supply tumors, thereby slowing tumor growth. Bevacizumab is classified as a monoclonal antibody and is widely recognized in medical literature for its role in cancer therapy.

Investigated diseases

NF2-related schwannomatosis – This is a genetic disorder characterized by the development of non-cancerous tumors called schwannomas, primarily affecting the nervous system. These tumors commonly form on the vestibular nerves, which are responsible for balance and hearing, leading to symptoms such as hearing loss, balance issues, and tinnitus. The condition is caused by mutations in the NF2 gene, which normally helps control cell growth. As the disease progresses, additional schwannomas may develop on other nerves, potentially affecting other cranial nerves and spinal nerves. The growth of these tumors can lead to various neurological symptoms depending on their location. The progression of the disease varies among individuals, with some experiencing more severe symptoms than others.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512860-75-00Estimated enrolment24 patientsSponsorLeids Universitair Medisch Centrum (LUMC)

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).